Global Needles Market to Reach $14.7 Billion by 2035 at 6.1% CAGR | BD, B. Braun, Terumo Corporation

The global needles market, valued at USD 7.7 billion in 2024, will reach USD 8.1 billion in 2025 and climb to USD 14.7 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.1% over the forecast period. This near-doubling of market value reflects accelerating demand from chronic disease management, expanding immunization programs, and material science advances that are making needles safer, less painful, and more suited to at-home use.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/needles-market/request-sample.html

Market Overview
Medical needles are among the most widely used tools in healthcare, serving functions that range from drug delivery and blood collection to wound closure and vaccine administration. The World Health Organization estimates that more than 16 billion injections are administered globally each year, while over 7.5 billion needles are used annually in home care settings alone by patients managing conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis. This volume reflects not just clinical demand but a structural shift: patients are increasingly self-managing chronic diseases at home, and the needle is their primary delivery tool.

Market growth is further accelerated by a string of recent industry investments. In January 2025, Becton, Dickinson and Company (BD) announced plans to expand U.S. manufacturing capacity for syringes, needles, and IV catheters. That same month, Terumo launched its INFINO Development Program with an injection filter needle incorporating a 5-micrometer polyamide mesh filter to block particle contamination during injections. In April 2025, Cook Medical entered a collaboration with Mendaera to develop needle-based urological solutions integrating specialized needles with handheld robotic technology. These moves signal that the sector's largest players are actively investing in both capacity and capability.

The GLP-1 drug boom is creating a secondary wave of demand. As GLP-1 receptor agonists gain widespread adoption for diabetes and obesity management, insulin pen needle volumes are rising sharply. Major manufacturers with pharmaceutical primary packaging businesses are also targeting value-added formats such as ready-to-use prefilled syringes, a segment that commands premium pricing and stickier customer relationships.

Key Growth Drivers
Rising chronic disease prevalence. Over 50% of the U.S. population lives with some form of chronic disease, according to the Center for Managing Chronic Disease at the University of Michigan. In Asia-Pacific, the Indian Journal of Public Health estimates that approximately 8.5 million deaths occur annually from chronic conditions. Daily injection regimens for conditions like diabetes, multiple sclerosis, and rheumatoid arthritis are creating a baseline of recurring demand that grows as the patient population expands.

Expanding global vaccination programs. Governments worldwide are broadening the scope of their immunization programs to cover diseases such as polio, diphtheria, and Hepatitis B. India's Universal Immunization Program, which provides free vaccines against multiple preventable diseases, exemplifies the policy momentum behind this driver. Each vaccine administered requires a needle, making public health programs a reliable and large-volume demand source.

Technological advances in needle design. Developments in ultra-thin pen needles, wider gauge sizing for high-viscosity drugs, retractable safety mechanisms, and microneedle platforms are expanding the clinical utility of needles and opening new market segments. In November 2023, Terumo India launched an insulin syringe with a 3-bevel sharp needle coated with high-grade silicone that reduces patient discomfort on insertion. Owen Mumford's April 2025 launch of low-cost pen needles, UnifineOTC, shows the market also moving toward accessibility and affordability.

Growth of home healthcare. The home healthcare end-user segment is projected to grow at approximately 9% CAGR through 2035, the fastest among all end-user categories. As patients with chronic diseases seek cost-effective alternatives to repeated hospital visits, demand for self-injectable formats and compatible needle products will continue rising.

Safety regulation and needle-stick injury prevention. The Occupational Safety and Health Administration (OSHA) reported that around 35% of sharps-related injuries in 2024 occurred during needle disposal, keeping regulatory focus firmly on safety-engineered devices. This drives procurement decisions toward safety needles with built-in retractable tips and protective caps.

Market Segmentation
By design, conventional needles currently hold close to 70% of the global needles market share in 2025, reflecting their entrenched use across the full spectrum of clinical procedures. Safety needles account for approximately 30% of the market but are growing faster, with a projected CAGR exceeding 8% through 2035, as hospitals and institutional buyers prioritize sharps injury reduction.

By purpose, syringe needles dominate with nearly 65% of overall market share in 2025, given their fundamental role in drug administration, blood collection, and IV procedures. Pen needles represent one of the most dynamic sub-segments, directly tied to insulin and GLP-1 delivery demand. By material, stainless steel commands close to 90% of the current market; however, plastic needles are growing at above 7% CAGR, driven by cost advantages and improved waste management properties in home-use applications. By end user, hospitals and clinics hold more than 55% of the market in 2025.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/needles-market/request-quote.html

Regional Insights
Asia-Pacific holds the largest regional share of the global needles market at approximately 40% in 2025, a position the region is expected to maintain through the forecast period. This dominance reflects a combination of factors: the region is home to a high concentration of established manufacturers, including Terumo Corporation, Nipro Corporation, Greiner Bio-One International, Kawamoto, and PENTAX Medical. Advanced research infrastructure and high chronic disease burden across China, Japan, and India sustain both production volumes and end-user demand. Additionally, population scale and expanding government immunization programs in India and Southeast Asia are pulling demand higher. More than 50% of the 475-plus needle providers profiled in the Roots Analysis report are headquartered in Asia-Pacific.

North America, while holding a smaller overall share, is projected to grow at a relatively higher CAGR than Asia-Pacific during the forecast period. The region's large number of hospitals and clinics, combined with BD's announced domestic manufacturing expansion and strong institutional procurement of safety devices, positions it as the fastest-growing major region.

Competitive Landscape
The global needles market features more than 475 companies spanning very large multinationals to small regional manufacturers. Key players profiled in the Roots Analysis report include BD, Medtronic, Olympus, Thermo Fisher Scientific, B. Braun, BIOTRONIK, Gerresheimer, Novo Nordisk, Roche, Lars Medicare, SB-KAWASUMI LABORATORIES, Wuzhou Medical, and Aleda Makina, among many others.

The competitive dynamic combines consolidation at the top with active partnership activity throughout the value chain. Acquisitions are the dominant deal type; in August 2024, Italy-based Medical Technology and Devices (MTD) acquired the pen needles and blood glucose monitoring device business of Ypsomed, which lifted MTD's pen needle production capacity to more than 2.5 billion units. Distribution and commercialization agreements are also common, as mid-sized manufacturers seek broader geographic reach without building wholly-owned sales infrastructure. The primary battlegrounds are manufacturing scale, regulatory compliance for safety device requirements, and speed-to-market for new delivery formats suited to biologics and self-injection applications.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/needles-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.